The Academy of Managed Care Pharmacy thinks there’s a better way for health plans and pharmacy benefit managers to make formulary decisions than by simply looking at line-item budget figures.
AMCP will test a set of guidelines for pharmacy and therapeutics committees to follow when adding or removing products from formularies. Intending its guidelines to “rationalize” decision making, AMCP will study the effect of formulary decisions on outcomes for given populations. The guidelines also are meant to assist drug manufacturers in producing economic data that are useful to P&T committees.
The standards are modeled on submission guidelines used at Seattle’s Regence Blue Shield.
More like this
- System Helps P&T Committees Get Pharmacoeconomic Data They Need
- Satisfying the P&T Committee’s Need for More Evidence
- Plans Look Askance at Me-Too Medications
- More cost-shifting in the pharmacy benefit: Copayments at new highs, while 3-tier formularies spread
- Formulary Submission Process Catches On… Slowly
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.